Accessibility Menu
Greater Cannabis logo

Greater Cannabis(OTC) GCAN

Market Cap$248.60KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)-100%
5 Year-97%
1 Year-17%
1 Month+36%
$0.25
+0%
+0.00Today
Greater Cannabis last closing stock price
MetricPriceDate
Last closeUSD 0.252026-07-27
Greater Cannabis stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-7.44%USD 0.272026-07-20
1 month+36.03%USD 0.182026-06-26
3 month+48.92%USD 0.172026-04-24
Year to date+233.33%USD 0.082025-12-31
1 year-16.67%USD 0.302025-07-25
3 year-76.19%USD 1.052023-07-28
5 year-96.88%USD 8.032021-07-28
Since inception-99.88%USD 209.992018-09-18

Greater Cannabis Financials at a Glance

Market Cap

$248.60KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$122.57K

EPS (TTM)

-$0.17

P/E Ratio

-1.45

Dividend

$0.00

Beta (Volatility)

-0.23 (Low)

Price

$0.25

Volume

3,572

Open

$0.25

Previous Close

$0.25

Daily Range

$0.25 - $0.25

52-Week Range

$0.04 - $0.67

Estimated Earnings Date

Mar 31, 2023

GCAN News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Greater Cannabis

Greater Cannabis develops therapies using cannabis compounds for brain-related disorders. Its oral patch delivers medicine through the mouth lining. These products aim to help people with conditions like autism or Parkinson’s disease.

Products and Services

  • Cannabinoid Therapeutics: Treatments using cannabis-derived compounds for neuropsychiatric disorders; 0% of revenue in 2025.
  • Oral Transmucosal Patch: A patch placed inside the mouth for medicine absorption; 0% of revenue in 2025.
  • Licensed Therapies: Exclusive rights to develop and sell a cannabinoid therapy from Shaare Zedek Scientific for brain disorders; 0% of revenue in 2025.
  • Research and Development: Ongoing work on new cannabis-based drug formulas; no direct revenue contribution in 2025.

Growth and Expansion

  • Signed exclusive license and joint R&D agreement with Shaare Zedek Scientific in 2021.
  • Shifted focus from e-commerce to drug development in 2018.
  • Completed preclinical studies in February 2024 and received approval for Phase II clinical trials in July 2023.
  • Implemented a 1-for-1,500 reverse stock split in October 2025.
  • Created Series B Convertible Preferred Stock for CEO voting control in 2025.

What Makes Greater Cannabis Stand Out

The company uses a unique oral patch to deliver cannabis-based drugs without swallowing pills. Its exclusive partnership with a major Israeli medical center gives access to novel therapies. Operations are lean, with only one full-time employee and a focus on research.

Five Things You Need to Know

  • No revenue reported for 2025, 2024, or 2023.
  • Net loss was $331,612 in 2025, up 85.2% from 2024.
  • Cash at year-end 2025 was $815, down from $57,368 in 2024.
  • Negative working capital of $741,649 as of December 31, 2025.
  • Auditor raised substantial doubt about the company’s ability to continue operating.

Bottom Line

Greater Cannabis has shifted to drug development but faces ongoing financial challenges. Its future depends on securing funding and advancing clinical trials.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

1

CEO

Aitan Zacharin

Website

www.gcanrx.com

Headquarters

Baltimore, MD 21209, US

GCAN Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

13.26%

Return on Capital

N/A

Return on Assets

-8517.79%

Earnings Yield

-68.97%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$248.60KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

994.40K

Volume

3.57K

Avg. Volume

3.54K

Financials (TTM)

Gross Profit

$417.00

Operating Income

-$172.85K

EBITDA

-$261.38K

Operating Cash Flow

-$53.37K

Capital Expenditure

$0.00

Free Cash Flow

-$53.37K

Cash & ST Invst.

$1.44K

Total Debt

$268.60K

Greater Cannabis Performance Analysis

Greater Cannabis annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Greater Cannabis sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Greater Cannabis annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.92-50.4%
20232023-12-31USD -0.38-59.0%
20242024-12-31USD -0.33-12.0%
20252025-12-31USD -0.4021.8%
Greater Cannabis sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-200.0%
Q32025-09-30-13233.3%
Q42025-12-31201.0%
Q12026-03-31-100.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

+100.0%

Gross Margin

0.00%

N/A

Market Cap

$248.60KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$248.60K

N/A

Employees

1

N/A

Net Income

-$33.38K

+86.2%

EBITDA

-$33.27K

+67.1%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$1.44K

-96.9%

Total Debt

$268.60K

-27.7%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$268.60K

-27.7%

Return on Assets

-85.18%

N/A

Return on Invested Capital

22.30%

N/A

Free Cash Flow

-$4.38K

+60.8%

Operating Cash Flow

-$4.38K

+60.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SETOSETO Holdings, Inc.
$0.01+0.00%
GREHGreen Rain Energy Holdings Inc.
$0.01-1.45%
BBBTBlack Bird Biotech, Inc.
$0.00+0.00%
CANLCannLabs, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOFISoFi Technologies
$15.25-0.09%
INTCIntel
$81.88-0.05%
NVDANvidia
$190.01-0.04%
TQQQProShares Trust - ProShares UltraPro Qqq
$57.75-0.06%

Questions About GCAN

What is the current price of Greater Cannabis?

Greater Cannabis is trading at $0.25 per share.

What is the 52-week range for Greater Cannabis?

Over the past 52 weeks, Greater Cannabis has traded between $0.04 and $0.67.

How much debt does Greater Cannabis have?

As of the most recent reporting period, Greater Cannabis reported total debt of $268.60K.

How much cash does Greater Cannabis have on hand?

Greater Cannabis reported $1.44K in cash and cash equivalents in its most recent financial results.

What is Greater Cannabis’s dividend yield?

Greater Cannabis does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services